Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]
- Resource Type
- Erratum
- Source
- In
Schizophrenia Research August 2022 246:258-259 - Subject
- Language
- ISSN
- 0920-9964